Lorin Sanchez, MD
Nephrology · Lawrenceville, GANPI 1982873832
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (36.4%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Amgen accounts for 61.8% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2023 at $8,766 and has fallen 78.0% since, to $1,930 in 2025. Among nephrology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 378 payments — averaging $60.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$14K
- Calliditas Therapeutics US Inc.$2K
- Vifor Pharma, Inc.$1K
- AstraZeneca$749
- OPKO Pharmaceuticals, LLC$615
- Mallinckrodt Hospital Products Inc.$564
- plus $3K from 21 others
Across 12 payments — averaging $4592.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$53K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
What the payments were for
- Consulting fees$5,72525%
- Speaking & faculty fees$5,29523%
- Travel & lodging$2,65212%
- Food & beverage$8,28336%
- Education$8244%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 107 | $14,075 |
| Calliditas Therapeutics US Inc. | 6 | $2,128 |
| Vifor Pharma, Inc. | 35 | $1,245 |
| AstraZeneca | 30 | $749 |
| OPKO Pharmaceuticals, LLC | 38 | $615 |
| Mallinckrodt Hospital Products Inc. | 8 | $564 |
| Novartis | 16 | $456 |
| Aurinia Pharma U.S., Inc. | 14 | $389 |
| Bayer | 14 | $362 |
| Otsuka America Pharmaceutical, Inc. | 14 | $314 |
| Fresenius USA Marketing, Inc. | 17 | $301 |
| Travere Therapeutics, Inc. | 27 | $291 |
| Apellis Pharmaceuticals, Inc. | 3 | $172 |
| ANI Pharmaceuticals, Inc. | 6 | $163 |
| Akebia Therapeutics Inc | 8 | $156 |
| GSK | 8 | $154 |
| Ardelyx, Inc. | 7 | $143 |
| Daiichi Sankyo Inc. | 6 | $113 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $86 |
| Sanofi | 3 | $84 |
| Boehringer Ingelheim | 3 | $60 |
| Baxter Healthcare | 1 | $39 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Nxstage Medical, Inc. | 1 | $29 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
| Incyte Corporation | 1 | $18 |
| Lemaitre Vascular, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,779 in reported general payments places this provider in the 90th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 31 | $146,426 |
| FarxigaDapagliflozin Propanediol | 58 | $83,256 |
| KerendiaFinerenone | 34 | $56,666 |
| AuryxiaFerric Citrate | 30 | $54,686 |
| VeltassaPatiromer Calcium Sorbitex | 17 | $20,373 |
| RayaldeeCalcifediol | 14 | $19,852 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $19,810 |
| Sevelamer Carbonate | 38 | $6,219 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 14 | $4,293 |
| Mycophenolate Mofetil | 12 | $4,061 |
| Calcitriol | 198 | $2,187 |
| Nifedipine ErNifedipine | 39 | $1,383 |
| Calcium Acetate | 18 | $1,156 |
| Allopurinol | 105 | $918 |
| Doxazosin Mesylate | 45 | $753 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $749 | $103,06575 claims |
| BayerKerendia | $362 | $56,66634 claims |
| Akebia Therapeutics IncAuryxia | $156 | $54,68630 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $615 | $19,85214 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $163 | $45514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 nephrology providers in Georgia.
Other nephrology in Lawrenceville
- James TumlinLawrenceville$434K
- William PaxtonLawrenceville$73K
- Sharad VirmaniLawrenceville$55K
- Aakash AminLawrenceville$22K
- Kathryn ElmoreLawrenceville$12K
- Shaun ConlonLawrenceville$11K
- Nnamdi NwaohiriLawrenceville$11K
- Jusong ChoiLawrenceville$8K
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.